| Product Name | Human Kallikrein-4 (KLK4) ELISA Kit |
|---|---|
| Description | Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. KLK4 was predominantly expressed in nuclei of basal cells in the prostate epithelium, in keeping with its distribution in prostate cancer cells in vitro. Adenovirus-mediated KLK4 expression dramatically induced proliferation of prostate cancer cells, at least in part, through significant alterations in cell cycle regulatory gene expression. Consistent with this data, small interfering RNA-mediated knockdown of endogenous KLK4 in LNCaP prostate cancer cells inhibited cell growth. This assay has high sensitivity and excellent specificity for detection of Human KLK4. No significant cross-reactivity or interference between Human KLK4 and analogues was observed. |
| Synonyms | AI2A1, ARM1, EMSP, EMSP1, KLK-L1, MGC116827, MGC116828, PROSTASE, PRSS17, PSTS, androgen-regulated message 1|enamel matrix serine protease 1|kallikrein 4 (prostase, enamel matrix, prostate)|kallikre |
| Method | Sandwich ELISA |
| Detection Range | 0.156-10 ng/mL |
| Sensitivity | 0.049 ng/mL |
| Reactivity | Human |
| Sample Types | Serum, Plasma, Other biological fluids. |
| Background |
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. KLK4 was predominantly expressed in nuclei of basal cells in the prostate epithelium, in keeping with its distribution in prostate cancer cells in vitro. Adenovirus-mediated KLK4 expression dramatically induced proliferation of prostate cancer cells, at least in part, through significant alterations in cell cycle regulatory gene expression. Consistent with this data, small interfering RNA-mediated knockdown of endogenous KLK4 in LNCaP prostate cancer cells inhibited cell growth. |
| Supplier | Abebio |
All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
